Published in Blood on January 07, 2011
The diversity of the immune response to the A2 domain of human factor VIII. Blood (2013) 0.96
Gene therapy for haemophilia: prospects and challenges to prevent or reverse inhibitor formation. Br J Haematol (2011) 0.86
A major determinant of the immunogenicity of factor VIII in a murine model is independent of its procoagulant function. Blood (2012) 0.79
Detection of intracellular Factor VIII protein in peripheral blood mononuclear cells by flow cytometry. Biomed Res Int (2013) 0.76
Small ncRNA Expression-Profiling of Blood from Hemophilia A Patients Identifies miR-1246 as a Potential Regulator of Factor 8 Gene. PLoS One (2015) 0.75
Missense mutations near the N-glycosylation site of the A2 domain lead to various intracellular trafficking defects in coagulation factor VIII. Sci Rep (2017) 0.75
The chemical chaperone sodium 4-phenylbutyrate improves the secretion of the protein CA267T mutant in CHO-K1 cells trough the GRASP55 pathway. Cell Biosci (2015) 0.75
Gene splicing by overlap extension. Methods Enzymol (1993) 4.59
Hepatoma secretory proteins migrate from rough endoplasmic reticulum to Golgi at characteristic rates. Nature (1983) 4.12
Interactions of protein antigens with antibodies. Proc Natl Acad Sci U S A (1996) 3.53
Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost (2001) 3.13
High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med (2000) 2.86
Mutations in the ER-Golgi intermediate compartment protein ERGIC-53 cause combined deficiency of coagulation factors V and VIII. Cell (1998) 2.34
High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism. Thromb Haemost (2000) 2.15
The tertiary structure and domain organization of coagulation factor VIII. Blood (2007) 1.96
Synthesis, processing, and secretion of recombinant human factor VIII expressed in mammalian cells. J Biol Chem (1988) 1.96
Crystal structure of human factor VIII: implications for the formation of the factor IXa-factor VIIIa complex. Structure (2008) 1.93
Bleeding due to disruption of a cargo-specific ER-to-Golgi transport complex. Nat Genet (2003) 1.82
Expression of factor VIII by murine liver sinusoidal endothelial cells. J Biol Chem (1999) 1.54
Distribution of factor VIII mRNA and antigen in human liver and other tissues. Nature (1985) 1.51
pH-dependent denaturation of thrombin-activated porcine factor VIII. J Biol Chem (1990) 1.46
A molecular model for the triplicated A domains of human factor VIII based on the crystal structure of human ceruloplasmin. Blood (1997) 1.37
Elevated factor VIII levels and the risk of thrombosis. Arterioscler Thromb Vasc Biol (2001) 1.33
High level expression of recombinant porcine coagulation factor VIII. J Biol Chem (2002) 1.33
Clearance mechanisms of von Willebrand factor and factor VIII. J Thromb Haemost (2007) 1.31
Mild hemophilia A caused by increased rate of factor VIII A2 subunit dissociation: evidence for nonproteolytic inactivation of factor VIIIa in vivo. Blood (1999) 1.28
Expression of the amino-terminal half-molecule of human serum transferrin in cultured cells and characterization of the recombinant protein. Biochemistry (1990) 1.28
Identification of porcine coagulation factor VIII domains responsible for high level expression via enhanced secretion. J Biol Chem (2003) 1.21
Subunit structure of thrombin-activated porcine factor VIII. Biochemistry (1989) 1.21
Differential interaction of coagulation factor VIII and factor V with protein chaperones calnexin and calreticulin. J Biol Chem (1998) 1.20
FVIII production by human lung microvascular endothelial cells. Blood (2006) 1.19
Coagulant properties of hybrid human/porcine factor VIII molecules. J Biol Chem (1992) 1.19
Purification of human factor VIII:C and its characterization by Western blotting using monoclonal antibodies. Biochemistry (1985) 1.16
Mild hemophilia A. J Thromb Haemost (2009) 1.13
The humoral response to human factor VIII in hemophilia A mice. J Thromb Haemost (2006) 1.10
Biosynthesis, assembly and secretion of coagulation factor VIII. Blood Coagul Fibrinolysis (1997) 1.09
A1 subunit-mediated regulation of thrombin-activated factor VIII A2 subunit dissociation. J Biol Chem (2006) 1.07
Activation of human endothelial cells from specific vascular beds induces the release of a FVIII storage pool. Blood (2010) 1.06
Novel forms of B-domain-deleted recombinant factor VIII molecules. Construction and biochemical characterization. Eur J Biochem (1995) 1.06
Residues Glu2181-Val2243 contain a major determinant of the inhibitory epitope in the C2 domain of human factor VIII. Blood (1998) 1.01
A novel cause of mild/moderate hemophilia A: mutations scattered in the factor VIII C1 domain reduce factor VIII binding to von Willebrand factor. Blood (2000) 0.98
Mild/moderate haemophilia A: new insights into molecular mechanisms and inhibitor development. Haemophilia (2008) 0.97
Post-translational requirements for functional factor V and factor VIII secretion in mammalian cells. J Biol Chem (1994) 0.94
In non-severe hemophilia A the risk of inhibitor after intensive factor treatment is greater in older patients: a case-control study. J Thromb Haemost (2010) 0.91
Spectrum of mutations in CRM-positive and CRM-reduced hemophilia A. Genomics (1993) 0.90
Intracellular accumulation of factor VIII induced by missense mutations Arg593-->Cys and Asn618-->Ser explains cross-reacting material-reduced haemophilia A. Br J Haematol (2000) 0.90
Confocal microscopy analysis of native, full length and B-domain deleted coagulation factor VIII trafficking in mammalian cells. Thromb Haemost (2004) 0.88
Molecular mechanisms of mild and moderate hemophilia A. J Thromb Haemost (2003) 0.84
Analysis of protein folding and oxidation in the endoplasmic reticulum. Curr Protoc Cell Biol (2002) 0.82
The molecular basis for cross-reacting material-positive hemophilia A due to missense mutations within the A2-domain of factor VIII. Blood (1998) 0.81
Measurement of factor VIII. A potential risk factor for vascular disease. Arch Pathol Lab Med (1993) 0.77
Structure of the factor VIII C2 domain in a ternary complex with 2 inhibitor antibodies reveals classical and nonclassical epitopes. Blood (2013) 1.47
Expression and characterization of recombinant murine factor VIII. Thromb Haemost (2002) 1.47
High-resolution mapping of epitopes on the C2 domain of factor VIII by analysis of point mutants using surface plasmon resonance. Blood (2014) 1.46
Use of blood outgrowth endothelial cells for gene therapy for hemophilia A. Blood (2002) 1.38
High level expression of recombinant porcine coagulation factor VIII. J Biol Chem (2002) 1.33
Hematopoietic stem-cell gene therapy of hemophilia A incorporating a porcine factor VIII transgene and nonmyeloablative conditioning regimens. Blood (2007) 1.28
Identification of porcine coagulation factor VIII domains responsible for high level expression via enhanced secretion. J Biol Chem (2003) 1.21
Targeting tissue factor-expressing tumor angiogenesis and tumors with EF24 conjugated to factor VIIa. J Drug Target (2008) 1.17
Reduction of the inhibitory antibody response to human factor VIII in hemophilia A mice by mutagenesis of the A2 domain B-cell epitope. Blood (2004) 1.10
A1 subunit-mediated regulation of thrombin-activated factor VIII A2 subunit dissociation. J Biol Chem (2006) 1.07
High-level expression of porcine factor VIII from genetically modified bone marrow-derived stem cells. Blood (2006) 1.05
Lentiviral vector platform for production of bioengineered recombinant coagulation factor VIII. Mol Ther (2010) 1.03
High-dose factor VIII inhibits factor VIII-specific memory B cells in hemophilia A with factor VIII inhibitors. Blood (2005) 1.02
Nonclassical anti-C2 domain antibodies are present in patients with factor VIII inhibitors. Blood (2008) 1.02
Comparison of factor VIII transgenes bioengineered for improved expression in gene therapy of hemophilia A. Hum Gene Ther (2009) 0.99
The diversity of the immune response to the A2 domain of human factor VIII. Blood (2013) 0.96
Functional aspects of factor VIII expression after transplantation of genetically-modified hematopoietic stem cells for hemophilia A. J Gene Med (2010) 0.91
Enhanced biosynthesis of coagulation factor VIII through diminished engagement of the unfolded protein response. J Biol Chem (2011) 0.90
The comparative immunogenicity of human and porcine factor VIII in haemophilia A mice. Thromb Haemost (2009) 0.88
Characterization and solution structure of the factor VIII C2 domain in a ternary complex with classical and non-classical inhibitor antibodies. J Biol Chem (2013) 0.88
Insulin increases branched-chain alpha-ketoacid dehydrogenase kinase expression in Clone 9 rat cells. Am J Physiol Endocrinol Metab (2002) 0.88
Development and characterization of recombinant ovine coagulation factor VIII. PLoS One (2012) 0.83
Potentiation of thrombin generation in hemophilia A plasma by coagulation factor VIII and characterization of antibody-specific inhibition. PLoS One (2012) 0.82
Decreased factor VIII levels during acetaminophen-induced murine fulminant hepatic failure. Blood (2003) 0.82
Factor VIII expression in azoxymethane-induced murine fulminant hepatic failure. Blood (2002) 0.82
A quantitative measure of the efficacy of factor VIII in hemophilia A mice. Thromb Haemost (2003) 0.81
A major determinant of the immunogenicity of factor VIII in a murine model is independent of its procoagulant function. Blood (2012) 0.79
Epitope mapping via selection of anti-FVIII antibody-specific phage-presented peptide ligands that mimic the antibody binding sites. Thromb Haemost (2014) 0.78
Phenotypes of allo- and autoimmune antibody responses to FVIII characterized by surface plasmon resonance. PLoS One (2013) 0.78
Antithrombin affects hemostatic response to recombinant activated factor VII in factor VIII deficient plasma. Anesth Analg (2008) 0.78
Contribution of A1 subunit residue Q316 in thrombin-activated factor VIII to A2 subunit dissociation. Biochemistry (2007) 0.77
Rapid generation of stable cell lines expressing high levels of erythropoietin, factor VIII, and an antihuman CD20 antibody using lentiviral vectors. Hum Gene Ther Methods (2013) 0.76
Visualizing cancer and response to therapy in vivo using Cy5.5-labeled factor VIIa and anti-tissue factor antibody. J Drug Target (2014) 0.76
Prospective, multicenter study of postoperative deep-vein thrombosis in patients with haemophilia undergoing major orthopaedic surgery. Thromb Haemost (2016) 0.76
Leucine toxicity in a neuronal cell model with inhibited branched chain amino acid catabolism. Brain Res Mol Brain Res (2004) 0.76